TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21934634
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg S-equol/day (EQL10)
Study: 21934634
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg S-equol/day (EQL30)
Study: 17919544
Drug: Buprenorphine 0.002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.002 mg/kg IV
Study: 16199794
Drug: Free fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free fruit and vegetables for 6 months with instruction in meal planning and food preparation
Study: 14613984
Drug: Trastuzumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab combined with chemotherapy
Study: 1456485
Drug: Siriraj Spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Siriraj Spacer with 2 puffs of albuterol (100 micrograms/puff)
Study: 1553052
Drug: Heparin calcium
Normalized name: HEPARIN CALCIUM
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin calcium
Study: 28403576
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg on day 1, followed by prasugrel 10 mg once daily on days 2 to 7, then vorapaxar 40 mg and prasugrel 10 mg on day 8, followed by vorapaxar 2.5 mg and prasugrel 10 mg orally once daily on days 9 to 28
Study: 28403576
Drug: Vorapaxar 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 40 mg on day 1, followed by vorapaxar 2.5 mg once daily on days 2 to 21
Study: 24668226
Drug: Prasugrel 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 100 mg loading dose
Study: 17174640
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose
Study: 9671874
Drug: Liarozole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liarozole (300 mg two times daily)
Study: 9671874
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) (100 mg two times daily)
Study: 2725926
Drug: Sulglicotide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulglicotide (200 mg t.i.d)
Study: 4758573
Drug: Digoxin tablets
Normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin tablets (0.25 mg)
Study: 4758573
Drug: Absorption sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorption sensitivity to dissolution rate
Study: 27159955
Drug: Reamberin (1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (1.5% solution, 10 mL/kg body weight intravenously once a day for up to 3 days)
Study: 27159955
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment regimen (control group)
Study: 25326035
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behavioural treatment (10 face-to-face and 9 online sessions)
Study: 25326035
Drug: Traditional face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional face-to-face cognitive behavioural treatment (20 weekly sessions)
Study: 25326035
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behavioural treatment
Study: 25326035
Drug: Traditional face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional face-to-face cognitive behavioural treatment
Study: 23173252
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy applied to specific acupoints (Baihui, Shenmen, Shenting, Sanyinjiao, Sishencong) 5 times a week for 8 weeks.
Study: 12402727
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (up to 300 mg)
Study: 9706926
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil 40 microg after lidocaine with epinephrine test dose
Study: 7631947
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg.kg‐1
Study: 8922769
Drug: Midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.15 mg.kg‐1
Study: 8922769
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg.kg‐1
Study: 7631947
Drug: Midazolam (0.1‐0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1‐0.15 mg.kg‐1)
Study: 2516707
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (4 micrograms/kg per minute for 3 hours)
Study: 2516707
Drug: Metoclopramide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide infusion (10 mg as a bolus)
Study: 2516707
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day for 3 months)
Study: 925382
Drug: live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: live attenuated A/Scotland/74 (H3N2) virus vaccine
Study: 31182263
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) for 12 months.
Study: 31182263
Drug: More potent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More potent antiplatelet agents (prasugrel and ticagrelor) compared to clopidogrel.
Study: 30885259
Drug: Lysulin™ supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysulin™ supplementation (two tablets three times a day)
Study: 29059197
Drug: Monthly email
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly email reminder intervention for doctors containing a list of patients overdue for a letter.
Study: 22027850
Drug: Daily stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily stretching (at least 6 times per week)
Study: 19570628
Drug: Hydroxysafflor yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxysafflor yellow A (HSYA) 35 mg
Study: 19570628
Drug: Hydroxysafflor yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxysafflor yellow A (HSYA) 70 mg
Study: 19570628
Drug: Hydroxysafflor yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxysafflor yellow A (HSYA) 140 mg
Study: 11181472
Drug: Tezosentan 20
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 20 mg/h
Study: 11181472
Drug: Tezosentan 50
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 50 mg/h
Study: 9886750
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with insulin or oral hypoglycaemic agents
Study: 9886750
Drug: Lower 2-h
Normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower 2-h plasma insulin
Study: 8299317
Drug: MK-0963 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0963 10 mg
Study: 8299317
Drug: MK-0963 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0963 25 mg
Study: 4923928
Drug: Amylobarbitone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylobarbitone 150 mg/day
Study: 19804626
Drug: Micafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)
Study: 19887460
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (3 mg/kg/day)
Study: 25624327
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment success
Study: 10096642
Drug: Elevated EPQ
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated EPQ score on the neuroticism subscale, short duration of treatment, slow onset of response to treatment
Study: 8677916
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (arm IV: i.a. and i.v. MMC + p.o. 5‐FU; arm V: i.v. MMC + p.o. 5‐FU) for rectal cancer
Study: 8677916
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (arm I: i.p. and i.v. MMC + p.o. 5‐FU; arm II: i.v. MMC + p.o. 5‐FU) for colonic cancer
Study: 8677916
Drug: Surgery only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery only (arm III for colonic cancer; arm VI for rectal cancer)
Study: 6433099
Drug: High urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High urea dialysance treatments
Study: 30367258
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment before each training session
Study: 28880050
Drug: Active patches
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patches
Study: 28880050
Drug: Sham patches
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham patches
Study: 22455413
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ixekizumab
Study: 22455413
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ixekizumab
Study: 22455413
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ixekizumab
Study: 18182600
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention plus metformin
Study: 18182600
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (750 mg/d)
Study: 15684150
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) therapy
Study: 8932976
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g supplemental calcium daily
Study: 2053000
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections of 80 mg triamcinolone acetonide plus 0.5% procaine hydrochloride in saline
Study: 6407500
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg and 75 mg)
Study: 6407500
Drug: Doxepin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (50 mg and 75 mg)
Study: 6407500
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg, 75 mg and 100 mg)
Study: 6407500
Drug: Doxepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (75 mg)
Study: 31806432
Drug: fentanyl target‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl target‐controlled infusion (fTCI)
Study: 25356046
Drug: pH capsule
Normalized name: Xymogen Panxyme PH Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH capsule
Study: 25356046
Drug: Conventional catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheter and pH capsule
Study: 20402816
Drug: 5-day amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID) and metronidazole (500 mg TID) for 9 days
Study: 20402816
Drug: 14-day amoxicillin
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 14-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID), metronidazole (500 mg TID), and amoxicillin (1 g BID) for 9 days
Study: 12433733
Drug: High pretreatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pretreatment serum concentration of bFGF (S-bFGF >= 17 pg/ml)
Study: 12433733
Drug: Low pretreatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pretreatment serum concentration of bFGF (S-bFGF < 17 pg/ml)
Study: 12433733
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with extensive-stage disease and high S-bFGF (>= 17 pg/ml)
Study: 10341329
Drug: Candidate standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate standard CC (liquid preparation)
Study: 8444211
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K supplementation at birth (n = 22)
Study: 8444211
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) vitamin K supplementation at birth (n = 18)
Study: 3021487
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (Tilade 4 mg q.i.d.)
Study: 27976591
Drug: Pulsed high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed high-intensity laser therapy (HILT) with total energy of 1500 J through three phases/3 sessions/week for three consecutive months
Study: 27976591
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy with the same physical therapy programme
Study: 27179167
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of RF and ultrasound cavitation
Study: 23265634
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT; Coping Cat)
Study: 23265634
Drug: Medication (sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (sertraline [SRT])
Study: 23265634
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and medication
Study: 16534103
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Coenzyme Q10 (CoQ10) at preferred dose (either 1800 mg or 2700 mg)
Study: 10934787
Drug: Glipizyd tabl.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizyd tabl. 5 mg
Study: 10934787
Drug: Glibenese tabl.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenese tabl. 5 mg
Study: 9887853
Drug: Five-day standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day standardized family-oriented clinical asthma training program with monthly follow-up for six months (Group 1)
Study: 9887853
Drug: Regular medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medical treatment according to international guidelines without a training program (Control Group)
Study: 3142349
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (500 mg)
Study: 26083537
Drug: Erythromycin lactobionate,
Normalized name: Erythromycin Lactobionate, lactobionate 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin lactobionate, 3 mg/kg, administered intravenously 15 minutes before tracheal intubation
Study: 26083537
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 15 minutes before tracheal intubation
Study: 16300126
Drug: Distal Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal Active Concept therapy
Study: 11196233
Drug: Edgewise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edgewise therapy (Control)
Study: 8769679
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment (continuous 17‐beta‐estradiol 2 mg and norethisterone acetate 1 mg per day)
Study: 8769679
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy (patches delivering continuous 17‐beta‐estradiol 0.05 mg/day with sequential oral medroxyprogesterone acetate 10 mg/day for 12 days/cycle)
Study: 3884627
Drug: Glucose plus
Normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose plus insulin (1 g + 1.5 U/kg bw X h) before and after ischaemic heart arrest
Study: 3884627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received glucose without insulin
Study: 30285187
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 5 × 104 cfu/g C. butyricum (CB2)
Study: 30285187
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 5 × 104 cfu/g C. butyricum (CB2) or 1 × 105 cfu/g (CB3)
Study: 29492637
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement (7.5 g of insoluble fibre per serving, twice daily for 2 years)
Study: 29492637
Drug: Placebo (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.8 g of insoluble fibre per serving, twice daily for 2 years)
Study: 2820202
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement
Study: 27585414
Drug: Propofol/remifentanil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/remifentanil 0.25 μg/kg/min (PRe‐0.25)
Study: 27585414
Drug: Propofol/remifentanil 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/remifentanil 0.125 μg/kg/min (PRe‐0.125)
Study: 27585414
Drug: Propofol/saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/saline solution (PS)
Study: 11399215
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy
Study: 1975277
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg qhs
Study: 1975277
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg qhs
Study: 1975277
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg qhs
Study: 375376
Drug: 15(R)15 methyl
Normalized name: METHYLAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(R)15 methyl prostaglandin E2 (free acid) at doses of 80, 140, 200, and 400 micrograms
Study: 375376
Drug: 15(R)15 methyl
Normalized name: METHYLAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(R)15 methyl prostaglandin E2 (methylester) at doses of 80, 140, and 200 micrograms
Study: 375376
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 80 micrograms methyl ester and 1.5 mg atropine sulphate
Study: 25975643
Drug: Multidisciplinary QOL-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary QOL-directed intervention (for those undergoing neoadjuvant therapy)
Study: 25975643
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical care (control group, for those undergoing neoadjuvant therapy)
Study: 19545384
Drug: Patient Perception
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient Perception of Study Medication (PPSM) questionnaire
Study: 15100619
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (24 g/day of white wine)
Study: 11778969
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (ST) with infusional chemotherapy (IC) using VAMP/C-VAMP followed by autologous transplantation and interferon maintenance
Study: 11778969
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy consolidation
Study: 8419199
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg on days 2 to 6 of the menstrual cycle
Study: 8419199
Drug: Cyclofenil 400
Normalized name: cyclofenil
DrugBank: Cyclofenil (DB13472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclofenil 400 mg on days 3 to 12 of the menstrual cycle
Study: 30500336
Drug: Self-administered lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered lidocaine gel 2% 20mL intravaginally 15-30min before procedure initiation
Study: 30500336
Drug: Self-administered lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered lidocaine gel
Study: 27465818
Drug: Tong Luo
Normalized name: CAMPHOR (NATURAL) 5 g / MENTHOL 3.4 g TRANSDERMAL POULTICE [TONG LUO QU TONG GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong Luo Hua Shi (TLHS) 4.8 g/day
Study: 27465818
Drug: Tong Luo
Normalized name: CAMPHOR (NATURAL) 5 g / MENTHOL 3.4 g TRANSDERMAL POULTICE [TONG LUO QU TONG GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong Luo Hua Shi (TLHS) 3.6 g/day
Study: 17629158
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cefaclor twice daily for five to seven days
Study: 17629158
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of cefaclor three times daily for five to seven days
Study: 16209246
Drug: IL-1ra urinary
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1ra urinary excretion
Study: 16209246
Drug: sTNFR I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTNFR I urinary excretion
Study: 16209246
Drug: sTNFR II
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTNFR II urinary excretion
Study: 16209246
Drug: uIL-1ra urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: uIL-1ra urinary excretion
Study: 11931374
Drug: Fibrinogen adsorption
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen adsorption treatment (4 treatments for healthy subjects, 144 treatments for patients)